{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
INN:eprociclovir [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Eprociclovir (A5021, 9-[[cis-1', 2'-bis(hydroxymethyl)cycloprop-1'-yl]methyl]guanine) is a nucleoside analog with antiviral activity. Antiviral activity of eprociclovir appears to depend rapid and stable accumulation of its triphosphate in infected cells and on inhibition of viral DNA polymerase by its triphosphate. Eprociclovir was shown to be a potent inhibitor of the replication of herpes simplex virus type 1, 2, 6, Epstein-Barr virus and varicella zoster virus, both in vitro and in vivo.
Eprociclovir development has been discontinued.
Status:
Investigational
Source:
NCT04469998: Phase 2 Interventional Completed Posterior Blepharitis
(2020)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
GW-870086 (now known as GSK 870086) was developed by GlaxoSmithKline as a glucocorticoid receptor agonist. Repeat inhaled doses of GW-870086 was studied in phase II clinical trial in patients with asthma. In addition, phase II clinical trial was investigated to determine the efficacy of GW-870086 ream formulation in subjects with moderate to severe atopic dermatitis. However, the development of this drug appears to have been discontinued.
Status:
Class (Stereo):
CHEMICAL (ACHIRAL)
Allocupreide is a copper(l) complex used as an antiinflammatory drug and antiarthritic agent. It was used for the treatment of trigeminal neuralgia.
Status:
Class (Stereo):
CHEMICAL (ACHIRAL)
Hedaquinium was studied as an antibacterial agent.
Status:
Investigational
Source:
NCT03678116: Not Applicable Interventional Completed Energy Metabolism
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT01972672: Phase 2 Interventional Completed Hepatocellular Carcinoma (HCC)
(2013)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Icaritin is a monoprenylated favonol with 4′-methoxyl from Epimedium Genus. It has been documented to have osteoblastic and neuroprotective activities. It can reduce the incidence of steroid-associated oesteonecrosis in rabbit with inhibition of both intravascular thrombosis and extravascular lipid deposition for maintaining the integrity of intraosseous vasculature. Icaritin shows anti-infammatory activity and inhibitory activities against cancer cells. The phase III clinical trial is planned for the treatment of Hepatocellular carcinoma.
Status:
Investigational
Source:
INN:mirivadelgat [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT01970215: Phase 2 Interventional Completed Dyslipidemia
(2013)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT00559182: Phase 1 Interventional Completed Advanced Cancer
(2007)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
MK-8033 is a dual c-Met/Ron inhibitor, which is under investigation by Merck for the treatment of cancer.
Status:
Investigational
Source:
NCT01081782: Phase 2 Interventional Completed Multiple Sclerosis
(2010)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Ceralifimod (ONO-4641) is an oral, selective Sphingosine 1-phosphate receptor 1 and 5 agonist. It was studied in the phase 2 trials for the treatment of multiple sclerosis, however, further, development was discontinued.
